Stock Research for ABBV

ABBV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABBV Stock Chart & Research Data

The ABBV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABBV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABBV Due diligence Resources & Stock Charts

The ABBV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABBV Detailed Price Forecast - CNN Money CNN View ABBV Detailed Summary - Google Finance
Yahoo View ABBV Detailed Summary - Yahoo! Finance Zacks View ABBV Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ABBV Trends & Analysis - Trade-Ideas Barrons View ABBV Major Holders - Barrons
NASDAQ View ABBV Call Transcripts - NASDAQ Seeking View ABBV Breaking News & Analysis - Seeking Alpha
Spotlight View ABBV Annual Report - CompanySpotlight.com OTC Report View ABBV OTC Short Report - OTCShortReport.com
TradeKing View ABBV Fundamentals - TradeKing Charts View ABBV SEC Filings - Bar Chart
WSJ View Historical Prices for ABBV - The WSJ Morningstar View Performance/Total Return for ABBV - Morningstar
MarketWatch View the Analyst Estimates for ABBV - MarketWatch CNBC View the Earnings History for ABBV - CNBC
StockMarketWatch View the ABBV Earnings - StockMarketWatch MacroAxis View ABBV Buy or Sell Recommendations - MacroAxis
Bullish View the ABBV Bullish Patterns - American Bulls Short Pains View ABBV Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ABBV Stock Mentions - StockTwits PennyStocks View ABBV Stock Mentions - PennyStockTweets
Twitter View ABBV Stock Mentions - Twitter Invest Hub View ABBV Investment Forum News - Investor Hub
Yahoo View ABBV Stock Mentions - Yahoo! Message Board Seeking Alpha View ABBV Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ABBV - SECform4.com Insider Cow View Insider Transactions for ABBV - Insider Cow
CNBC View ABBV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABBV - OTC Markets
Yahoo View Insider Transactions for ABBV - Yahoo! Finance NASDAQ View Institutional Holdings for ABBV - NASDAQ


Stock Charts

FinViz View ABBV Stock Insight & Charts - FinViz.com StockCharts View ABBV Investment Charts - StockCharts.com
BarChart View ABBV Stock Overview & Charts - BarChart Trading View View ABBV User Generated Charts - Trading View


Latest Financial News for ABBV

AbbVie And Other Great Pharma And Biotech Income Stocks
Posted on Friday April 20, 2018

Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...


Mylan NV Could Be Closer to a Breakout Than Most Traders Realize
Posted on Thursday April 19, 2018

If it seems like Mylan NV (NASDAQ:MYL) has gotten far more media attention of late than it usually does — almost all of it bullish — you’re not crazy. The recent investor-day event helped the company toot its own horn to be sure, still, MYL stock has been strangely stuck in neutral in recent days. It’s a curious situation that defies the news Mylan has been dishing out that’s been turning some heads.


Gilead Sciences Expects Decline in Earnings in Fiscal 2018
Posted on Thursday April 19, 2018

Gilead Sciences (GILD) expects to witness non-GAAP gross product margin in the range of 85% to 87% in fiscal 2018. The company has also projected non-GAAP research and development (or R&D) and selling, general, and administrative (or SG&A) expenses in the range of $3.4 billion to $3.6 billion, respectively. The company has also projected a diluted earnings per share (or EPS) impact of $0.41 to $1.51, attributable to stock-based compensation paid for acquisitions and other related expenses.


Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising
Posted on Thursday April 19, 2018

The global pharmaceutical industry will see annual earnings growth of 1%-2% over the next 12 to 18 months, supporting a stable outlook on the sector, Moody's Investors Service says in its just-released report. The rating agency's stable outlook and modest EBITDA growth reflect solid underlying fundamentals, including rising utilization of prescription drugs, expansion in emerging markets and positive pricing trends in the US in many therapeutic areas. Among the diverse group of pharmaceutical companies rated by Moody's, those focusing on cancer drugs will see the highest EBITDA growth of more than 10%, while companies with a strong portfolio of products treating rare diseases will see solid growth in the 6%-10% range.


Enter a stock symbol to view the stock details.